Patients other than MSM | | | | |
• Anogenital | Ceftriaxone (250 mg IM, single dose) in combination with azithromycin† (1 g orally, single dose) | A, II13 | Spectinomycin (2 g IM, single dose) in combination with azithromycin† (1 g orally, single dose) | B, III14,15 |
Cefixime‡ (800 mg, single dose) in combination with azithromycin† (1 g orally, single dose) | B, II13 | Azithromycin§ (2 g orally, single dose) | B, I16–19 |
• Pharyngeal | Ceftriaxone (250 mg IM, single dose) in combination with azithromycin† (1 g orally, single dose) | A, II13 | Cefixime‡ (800 mg, single dose) in combination with azithromycin† (1 g orally, single dose) | B, II13 |
| | Azithromycin§ (2 g orally, single dose) | B, I16–19 |
MSM | | | | |
• Anogenital | Ceftriaxone (250 mg IM, single dose) in combination with azithromycin† (1 g orally, single dose) | A, II13 | Cefixime‡ (800 mg, single dose) in combination with azithromycin† (1 g orally, single dose) | B, II13 |
| | Spectinomycin (2 g IM, single dose) in combination with azithromycin† (1 g orally, single dose) | B, III14,15 |
| | Azithromycin§ (2 g orally, single dose) | B, I16–19 |
• Pharyngeal | Ceftriaxone (250 mg IM, single dose) in combination with azithromycin† (1 g orally, single dose) | A, II13 | Cefixime‡ (800 mg, single dose) in combination with azithromycin† (1 g orally, single dose) | B, II13 |